financetom
Business
financetom
/
Business
/
Canada's Silvercorp Q1 revenue up 13%
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canada's Silvercorp Q1 revenue up 13%
Aug 7, 2025 2:30 PM

Overview

* Silvercorp fiscal Q1 revenue rises 13% yr/yr to C$81.3 mln

* Adjusted net income for fiscal Q1 up 2% to C$21.0 mln

* Fatality at Ying Mining District may impact future production

Outlook

* Silvercorp expects a 20-25% production shortfall due to mine closures in the current quarter

Result Drivers

* HIGHER METAL PRICES - Revenue increase driven by 12% rise in silver prices and 45% rise in gold prices

* PRODUCTION COSTS - Increased ore processing led to higher production costs, impacting income from mine operations

* DERIVATIVE CHARGES - Net income affected by C$4.8 mln charge on derivative liabilities

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 C$81.33

Revenue mln

Q1 C$0.1

Adjusted

EPS

Q1 EPS C$0.08

Q1 C$21.05

Adjusted mln

Net

Income

Q1 Net C$18.13

Income mln

Q1 Basic C$0.08

EPS

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the non-gold precious metals & minerals peer group is "buy"

* Wall Street's median 12-month price target for Silvercorp Metals Inc ( SVM ) is C$7.50, about 14.8% above its August 6 closing price of C$6.39

* The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gyre Therapeutics Says China's NMPA Approves Pirfenidone Trial in Lung Injury
Gyre Therapeutics Says China's NMPA Approves Pirfenidone Trial in Lung Injury
Mar 31, 2025
10:06 AM EDT, 03/31/2025 (MT Newswires) -- Gyre Therapeutics ( GYRE ) said Monday that China's National Medical Products Administration approved its application to conduct a clinical trial evaluating pirfenidone capsules for radiation-induced lung injury, with or without immune-related pneumonitis. The company said it expects to start the phase 2/3 trial to assess dosing and efficacy in H2 2025 at...
TPG RE Finance Closes $1.1 Billion Commercial Real Estate Collateralized Loan Obligation
TPG RE Finance Closes $1.1 Billion Commercial Real Estate Collateralized Loan Obligation
Mar 31, 2025
10:12 AM EDT, 03/31/2025 (MT Newswires) -- TPG RE Finance Trust ( TRTX ) said Monday it closed a $1.1 billion managed commercial real estate collateralized loan obligation on Friday. The company placed $962.5 million of investment-grade securities with institutional investors, providing it with term financing on a non-mark-to-market, non-recourse basis, it said, adding that the obligation has a 30-month...
NeOnc Technologies Holdings' Perillyl Alcohol Receives FDA's Rare Pediatric Disease Designation
NeOnc Technologies Holdings' Perillyl Alcohol Receives FDA's Rare Pediatric Disease Designation
Mar 31, 2025
10:03 AM EDT, 03/31/2025 (MT Newswires) -- NeOnc Technologies Holdings ( NTHI ) said Monday that the US Food and Drug Administration has granted rare pediatric disease designation to perillyl alcohol, also known as NEO100, for the treatment of pediatric-type diffuse high-grade gliomas. The company said the FDA designation was based on findings that pediatric-type diffuse high-grade gliomas meets the...
Abbott Laboratories Says Trial Results Show Benefits of TriClip System for People With Leaky Heart Valves
Abbott Laboratories Says Trial Results Show Benefits of TriClip System for People With Leaky Heart Valves
Mar 31, 2025
10:05 AM EDT, 03/31/2025 (MT Newswires) -- Abbott Laboratories ( ABT ) said Monday new results from a trial showed that the TriClip transcatheter edge-to-edge repair system to treat leaky heart valves provided substantial and sustained improvements in the severity of the condition after two years. The data also showed that that the device significantly reduced the rate of heart...
Copyright 2023-2026 - www.financetom.com All Rights Reserved